AU2018234709B2 - Anti-PHF-tau antibodies and uses thereof - Google Patents

Anti-PHF-tau antibodies and uses thereof Download PDF

Info

Publication number
AU2018234709B2
AU2018234709B2 AU2018234709A AU2018234709A AU2018234709B2 AU 2018234709 B2 AU2018234709 B2 AU 2018234709B2 AU 2018234709 A AU2018234709 A AU 2018234709A AU 2018234709 A AU2018234709 A AU 2018234709A AU 2018234709 B2 AU2018234709 B2 AU 2018234709B2
Authority
AU
Australia
Prior art keywords
ser
gly
lys
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018234709A
Other languages
English (en)
Other versions
AU2018234709A1 (en
Inventor
Marianne BORGERS
Thomas Malia
Marc Mercken
Kristof VAN KOLEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AU2018234709A1 publication Critical patent/AU2018234709A1/en
Application granted granted Critical
Publication of AU2018234709B2 publication Critical patent/AU2018234709B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018234709A 2017-03-16 2018-03-16 Anti-PHF-tau antibodies and uses thereof Active AU2018234709B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16
US62/472,214 2017-03-16
PCT/US2018/022782 WO2018170351A1 (en) 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2018234709A1 AU2018234709A1 (en) 2019-08-29
AU2018234709B2 true AU2018234709B2 (en) 2024-10-31

Family

ID=63521020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018234709A Active AU2018234709B2 (en) 2017-03-16 2018-03-16 Anti-PHF-tau antibodies and uses thereof

Country Status (22)

Country Link
US (3) US10766953B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596119A4 (cg-RX-API-DMAC7.html)
JP (3) JP7159185B2 (cg-RX-API-DMAC7.html)
KR (2) KR102597462B1 (cg-RX-API-DMAC7.html)
CN (2) CN110799531B (cg-RX-API-DMAC7.html)
AR (1) AR111288A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018234709B2 (cg-RX-API-DMAC7.html)
CA (1) CA3055598A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002566A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992038A1 (cg-RX-API-DMAC7.html)
IL (2) IL268700B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20180021A1 (cg-RX-API-DMAC7.html)
MA (1) MA47789A (cg-RX-API-DMAC7.html)
MX (2) MX2019010922A (cg-RX-API-DMAC7.html)
MY (1) MY205672A (cg-RX-API-DMAC7.html)
PH (1) PH12019501973A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907754RA (cg-RX-API-DMAC7.html)
TW (1) TWI771389B (cg-RX-API-DMAC7.html)
UA (1) UA128385C2 (cg-RX-API-DMAC7.html)
UY (2) UY37635A (cg-RX-API-DMAC7.html)
WO (1) WO2018170351A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202101318B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2859665C (en) * 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別tau之抗體
KR102905634B1 (ko) * 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
PE20230385A1 (es) * 2020-04-08 2023-03-06 Janssen Biotech Inc Anticuerpos anti-phf-tau y usos de estos
MX2023000695A (es) * 2020-07-14 2023-04-20 Janssen Pharmaceutica Nv Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica.
JP2023546503A (ja) * 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ.ベー. 抗タウ抗体の安全な投与方法
CN116829582A (zh) * 2020-10-26 2023-09-29 詹森药业有限公司 安全施用抗Tau抗体的方法
AU2021367878A1 (en) * 2020-10-26 2023-06-22 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
CA3203800A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
CA3214310A1 (en) 2021-03-26 2022-09-29 Rupesh Nanjunda Anti-tau antibodies and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE154642T1 (de) 1991-10-25 1997-07-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
ATE335007T1 (de) 1993-12-21 2006-08-15 Innogenetics Nv Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
CA2195672A1 (en) 1994-07-29 1996-02-15 Eugeen Vanmechelen Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP4538461B2 (ja) * 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション,インコーポレイテッド ヒトIL−1βアンタゴニスト
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
RU2009107707A (ru) 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Also Published As

Publication number Publication date
US20210179696A1 (en) 2021-06-17
SG11201907754RA (en) 2019-09-27
AU2018234709A1 (en) 2019-08-29
TWI771389B (zh) 2022-07-21
IL268700B1 (en) 2024-03-01
CN110799531B (zh) 2023-08-04
PH12019501973A1 (en) 2020-06-29
US11365244B2 (en) 2022-06-21
ZA202101318B (en) 2023-03-29
BR122023021947A2 (pt) 2024-02-20
ZA202311412B (en) 2025-04-30
EP3596119A4 (en) 2021-01-13
CN110799531A (zh) 2020-02-14
JP2020513804A (ja) 2020-05-21
WO2018170351A8 (en) 2019-12-19
US20230047413A1 (en) 2023-02-16
IL268700B2 (en) 2024-07-01
TW201900682A (zh) 2019-01-01
MX2019010922A (es) 2019-11-08
UY37635A (es) 2018-09-28
MX2024015440A (es) 2025-02-10
US10766953B2 (en) 2020-09-08
AR111288A1 (es) 2019-06-26
CN117209599A (zh) 2023-12-12
MA47789A (fr) 2020-01-22
KR102695287B1 (ko) 2024-08-13
JP2022191383A (ja) 2022-12-27
US20180265575A1 (en) 2018-09-20
IL268700A (en) 2019-10-31
BR122023021958A2 (pt) 2024-02-20
CA3055598A1 (en) 2018-09-20
MY205672A (en) 2024-11-05
EP3596119A1 (en) 2020-01-22
CL2019002566A1 (es) 2019-12-27
UA128385C2 (uk) 2024-07-03
IL310464A (en) 2024-03-01
WO2018170351A1 (en) 2018-09-20
KR102597462B1 (ko) 2023-11-03
JP7159185B2 (ja) 2022-10-24
BR112019019049A2 (pt) 2020-04-22
JP2024088689A (ja) 2024-07-02
KR20230155025A (ko) 2023-11-09
KR20190130133A (ko) 2019-11-21
JOP20180021A1 (ar) 2019-01-30
UY40829A (es) 2024-08-15
EA201992038A1 (ru) 2020-02-06

Similar Documents

Publication Publication Date Title
US20230047413A1 (en) Anti-PHF-Tau Antibodies and Uses Thereof
CA2859665C (en) Anti-phf-tau antibodies and their uses
US10633435B2 (en) Anti-PHF-tau antibodies and uses thereof
CN115697393A (zh) 抗PHF-tau抗体及其用途
US20240150451A1 (en) Anti-tau antibodies and uses thereof
BR122023021958B1 (pt) Anticorpos anti-phf-tau, composição farmacêutica, e método in vitro de produção dos referidos anticorpos
EA049614B1 (ru) Анти-псф-тау-антитела и способы их применения
BR122023021947B1 (pt) Usos de anticorpos anti-phf-tau
BR112019019049B1 (pt) Anticorpos antiphf-tau, ácido nucleico isolado, vetor, e composição farmacêutica

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)